Biotech · Public company · San Diego, CA, US
Travere Therapeutics, Inc.
Ticker TVTX · SEC CIK 0001438533
Track this companyFree. Adds Travere Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials167 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline9
- DapagliflozinPhase 3 · Immunoglobulin A NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- FosmetpantotenatePhase 3 · Pantothenate Kinase-Associated NeurodegenerationClinicalTrials.gov · fetched Nov 12, 2026
- irbesartanPhase 3 · Immunoglobulin A NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- IrbesartanPhase 3 · Focal Segmental GlomerulosclerosisClinicalTrials.gov · fetched Nov 12, 2026
- PegtibatinasePhase 3 · HomocystinuriaClinicalTrials.gov · fetched Nov 12, 2026
- sparsentanPhase 3 · Focal Segmental GlomerulosclerosisClinicalTrials.gov · fetched Nov 12, 2026
- sparsentanPhase 3 · Immunoglobulin A NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- RE-021 (Sparsentan)Phase 2 · Focal Segmental GlomerulosclerosisClinicalTrials.gov · fetched Nov 12, 2026
- SparsentanProteinuriaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials16
- Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated ProteinuriaPHASE1 · RECRUITING · started Jul 10, 2026ClinicalTrials.gov NCT07224776 · fetched Nov 12, 2026
- Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental GlomerulosclerosisPHASE4 · ACTIVE_NOT_RECRUITING · started Oct 7, 2025ClinicalTrials.gov NCT07219121 · fetched Nov 12, 2026
- A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE)PHASE3 · ENROLLING_BY_INVITATION · started Apr 30, 2024ClinicalTrials.gov NCT06431893 · fetched Nov 12, 2026
- Rare Group Problem Management PlusNA · COMPLETED · started Feb 5, 2024ClinicalTrials.gov NCT06548022 · fetched Nov 12, 2026
- Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care TreatmentPHASE3 · RECRUITING · started Dec 28, 2023ClinicalTrials.gov NCT06247085 · fetched Nov 12, 2026
- A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgANPHASE2 · COMPLETED · started May 19, 2023ClinicalTrials.gov NCT05856760 · fetched Nov 12, 2026
- Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)COMPLETED · started Feb 5, 2022ClinicalTrials.gov NCT05200871 · fetched Nov 12, 2026
- Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesPHASE2 · RECRUITING · started Aug 12, 2021ClinicalTrials.gov NCT05003986 · fetched Nov 12, 2026
- ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening ProgramENROLLING_BY_INVITATION · started May 10, 2021ClinicalTrials.gov NCT05368038 · fetched Nov 12, 2026
- Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)PHASE1_PHASE2 · RECRUITING · started Jan 22, 2019ClinicalTrials.gov NCT03406611 · fetched Nov 12, 2026
- A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyPHASE3 · COMPLETED · started Dec 11, 2018ClinicalTrials.gov NCT03762850 · fetched Nov 12, 2026
- Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)PHASE3 · COMPLETED · started Apr 17, 2018ClinicalTrials.gov NCT03493685 · fetched Nov 12, 2026
- Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN ParticipantsPHASE3 · TERMINATED · started Jul 17, 2017ClinicalTrials.gov NCT03041116 · fetched Nov 12, 2026
- Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)COMPLETED · started Jan 1, 2017ClinicalTrials.gov NCT02998710 · fetched Nov 12, 2026
- Cerebrotendinous Xanthomatosis (CTX) Prevalence StudyCOMPLETED · started Sep 1, 2015ClinicalTrials.gov NCT02638220 · fetched Nov 12, 2026
- Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisPHASE2 · COMPLETED · started Mar 1, 2014ClinicalTrials.gov NCT01613118 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 21, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 21, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026